SDEV Stablecoin Development Corp

CIK 0001389545 44 ready 8-Ks latest May 20, 2026, 8:38 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 2 baseline Risk accumulating: auditor change (2)

Ready 8-Ks 44

Latest filing May 20, 2026, 8:38 AM ET

Top materiality 1.00

Event mix other_material ×28 · m_and_a ×7 · earnings ×2

Sentiment 10 pos · 15 neg · 19 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for SDEV

Highest-materiality recent filing

NovaBay to rename Stablecoin Development Corp; holds 2.06B SKY tokens (8.78% of supply)

March 23, 2026, 7:59 PM ET other material materiality 1.00 positive item 2.02 item 7.01 item 8.01 item 9.01

Name change to Stablecoin Development Corporation; ticker changes from NBY to SDEV effective Apr 3, 2026.
Holds approx. 2.06 billion SKY tokens (~8.78% of total supply) as of March 16, 2026.

Read filing →

May 20, 2026, 8:38 AM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

SDEV Q1 2026 operating income $22.3M vs loss $3.3M YoY; GAAP net income $552.4M driven by non-cash warrant gains

Operating income of $22.3 million vs operating loss of $3.3 million in Q1 2025; staking revenue $2.5M, unrealized gain on digital assets $22.7M.
April 29, 2026, 7:59 PM ET other material materiality 0.95 negative item 4.02 ◈ Auditor Changes

SDEV restates 2025 financials; warrant error increases net loss from $22.1M to $630.8M

Audit committee concludes 2025 financials non-reliable due to pre-funded warrant accounting error.
April 6, 2026, 7:59 PM ET other material materiality 0.60 neutral item 2.02 item 9.01

Stablecoin Dev Corp trades on NYSE American under SDEV; holds 2.15B SKY tokens (9.15% supply)

Name change to Stablecoin Development Corp effective April 2; ticker changed to SDEV.
April 1, 2026, 7:59 PM ET other material materiality 0.60 positive item 5.02 item 5.03 item 9.01 ◈ Governance Changes ×2

NovaBay shareholders approve 2026 equity plan; CEO gets ~19.6M RSUs/PSUs; name change to Stablecoin Development Corp

Stockholders approved 2026 Equity Incentive Plan on March 12, 2026, authorizing 22,223,927 initial shares plus annual increases.
March 23, 2026, 7:59 PM ET other material materiality 1.00 positive item 2.02 item 7.01 item 8.01 item 9.01

NovaBay to rename Stablecoin Development Corp; holds 2.06B SKY tokens (8.78% of supply)

Name change to Stablecoin Development Corporation; ticker changes from NBY to SDEV effective Apr 3, 2026.
March 12, 2026, 7:59 PM ET other material materiality 0.70 neutral item 5.03 item 5.07 item 9.01 ◈ Governance Changes

NovaBay shareholders approve 5B authorized shares, officer exculpation, and 2026 equity plan

Authorized common stock increased from 1.5B to 5B shares; prohibition on stockholder action by written consent removed.
February 20, 2026, 6:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 9.01 ◈ Governance Changes

NovaBay Pharmaceuticals effects 1-for-5 reverse stock split

Reverse stock split effective at 4:15 p.m. ET on Feb 20, 2026; trading on split-adjusted basis from Feb 23.
February 12, 2026, 6:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

NovaBay announces 1-for-5 reverse stock split effective Feb 20, 2026

Reverse split ratio 1-for-5; effective after market close on Feb 20, trading on split-adjusted basis Feb 23.
January 30, 2026, 6:59 PM ET other material materiality 0.30 neutral item 4.01 item 8.01 ◈ Auditor Changes

NovaBay hires CBIZ as auditor, sets special meeting for warrant exercise vote

Engaged CBIZ CPAs, P.C. as independent registered public accounting firm for FY 2025, effective January 30, 2026.
January 28, 2026, 6:59 PM ET other material materiality 0.70 negative item 4.01 item 9.01

NovaBay auditor Withum declines re-appointment; dissolution plan noted in prior audit

WithumSmith+Brown declined to stand for re-appointment as auditor for FY2025 as of Jan 22, 2026.
January 20, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 9.01 ◈ Material Agreements

NovaBay enters $100M ATM equity distribution agreement with Virtu Americas LLC

Company may sell up to $100M of common stock from time to time through Virtu as sales agent.
January 16, 2026, 6:59 PM ET other material materiality 0.90 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements

NovaBay raises $134M via pre-funded warrants, pivots to digital asset strategy focused on SKY tokens

Issued pre-funded warrants for 837.7M shares at $0.17/warrant, gross proceeds ~$134M.
October 22, 2025, 7:59 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

NovaBay creates Series E Non-Voting Convertible Preferred Stock

Filed Certificate of Designation for Series E Preferred Stock with Delaware on Oct 16, 2025.
October 21, 2025, 7:59 PM ET regulatory materiality 0.35 positive item 8.01 item 9.01

NovaBay regains NYSE American continued listing compliance by raising ~$8.15M

NYSE American notified NovaBay on Oct 20, 2025 that it resolved all deficiencies under Sections 1003(a)(i)-(iii).
October 20, 2025, 7:59 PM ET M&A materiality 0.80 neutral item 1.01 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 5.07 item 9.01 ◈ Governance Changes◈ M&A Transactions

NovaBay: Change of control as R01/Framework each own 45.1%; new CEO; reverse split approved

R01 Fund LP and Framework Ventures IV each beneficially own 45.1% of outstanding common stock post-conversion.
October 9, 2025, 7:59 PM ET leadership materiality 0.85 negative item 5.02 item 8.01

CEO David Lazar resigns; R01 and Framework to buy preferred shares, gaining ~90% ownership

CEO David Lazar resigned effective upon release of escrow funds from a securities purchase agreement.
September 18, 2025, 7:59 PM ET dividend materiality 0.55 positive item 7.01 item 9.01

NovaBay reminds of $0.80 special dividend due bill period and Oct 16 annual meeting

One-time special cash dividend of $0.80 per share payable Sept 29 to holders of record Sept 15.
August 26, 2025, 7:59 PM ET dividend materiality 0.60 positive item 8.01 item 9.01

NovaBay declares $0.80 special dividend; record date Sep 15, pay date Sep 29

Special cash dividend of $0.80 per common share declared by Board and Special Transaction Committee.
August 19, 2025, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 5.02 item 5.03 item 3.02 item 3.03 item 8.01 item 9.01 ◈ Governance Changes

NovaBay sells ~95% of diluted shares to David Lazar for $6M; names him CEO; plans special dividend

Lazar purchased 481,250 Series D preferred shares for $3.85M at First Closing; will buy 268,750 Series E shares for $2.15M later.
April 22, 2025, 7:59 PM ET other material materiality 0.90 negative item 5.07

NovaBay shareholders approve liquidation and dissolution plan

Proposal to dissolve company passed with 3,080,743 votes for, 42,531 against, 228 abstain.
March 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 9.01

NovaBay settles warrant disputes with Sabby, Bigger, District 2; secures voting support for dissolution

Sabby settlement: exercises 263,892 warrants at $0.66/share; company buys back remaining 1,008,834 warrants for $1.125M.
March 7, 2025, 6:59 PM ET other material materiality 0.75 negative item 1.01 item 8.01 item 9.01

NovaBay sets April 16 special meeting for dissolution vote; hires Lucid Capital for alternatives

Special meeting on April 16, 2025; record date March 18, 2025. Stockholders to vote on complete liquidation/dissolution.
February 4, 2025, 6:59 PM ET other material materiality 0.75 neutral item 5.07 item 8.01 item 9.01

NovaBay shareholders reject liquidation proposal; board plans new vote

On Jan 30, 2025, stockholders voted down Proposal Two (liquidation/dissolution); 49% of outstanding shares voted for, below the required >50%.
January 23, 2025, 6:59 PM ET other material materiality 0.90 negative item 2.01 item 5.07 item 8.01 item 5.02 item 9.01

NovaBay completes $11.5M Avenova asset sale; dissolution vote adjourned to Jan 30

Closed sale of Avenova eyecare business to PRN for $11.5M cash, net of $507,954 bridge loan payoff and $500K escrow.
January 22, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01

NovaBay extends CEO Justin Hall's employment term to Dec 31, 2025

Third Amendment to CEO Justin M. Hall's employment agreement extends his term through December 31, 2025.
January 10, 2025, 6:59 PM ET other material materiality 0.65 negative item 1.01 item 2.01 item 9.01

NovaBay sells wound care trademarks and inventory for $626,000 to Phase One Health LLC

Sold NeutroPhase, PhaseOne, OmniPhase trademarks for $500,000 to Phase One Health LLC.
December 19, 2024, 6:59 PM ET other material materiality 0.80 negative item 5.07 item 8.01 item 9.01

NovaBay special meeting adjourned again; asset sale and dissolution votes still short of needed 50% threshold

Special meeting reconvened Dec 18, 2024 adjourned to Jan 16, 2025 due to insufficient votes.
November 22, 2024, 6:59 PM ET other material materiality 0.80 negative item 5.07 item 8.01 item 9.01

NovaBay adjourns special meeting on asset sale and dissolution; insufficient votes, reconvenes Dec 18

Special meeting Nov 22: only 43% of shares represented, insufficient votes for 50% threshold.
November 6, 2024, 6:59 PM ET M&A materiality 0.70 neutral item 1.01 item 2.03 item 8.01 item 9.01

NovaBay revises Avenova sale to PRN; base price upped to $11.5M, bridge loan secured

Base purchase price for Avenova assets increased from $9.5M to $11.5M.
October 29, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

NovaBay receives superior offer from Refresh Acquisitions for Avenova at $11.5M

Refresh offers $11.5M base purchase price for Avenova assets, vs $9.5M from PRN.
October 16, 2024, 7:59 PM ET other material materiality 0.90 negative item 2.02 item 7.01

NovaBay reports $776K cash as of Sept 30; sets Nov 22 special meeting for asset sale and dissolution

Preliminary unaudited cash and cash equivalents of $776,000 as of September 30, 2024.
September 20, 2024, 7:59 PM ET M&A materiality 1.00 negative item 1.01 item 8.01 item 2.05 item 7.01 item 9.01

NovaBay to sell Avenova brand for $9.5M to PRN; plans dissolution

NovaBay signs definitive agreement to sell Avenova assets to PRN for $9.5M cash; closing expected Q4 2024.
July 29, 2024, 7:59 PM ET debt materiality 0.75 positive item 1.01 item 8.01 item 9.01

NovaBay raises ~$3.87M in public offering to redeem convertible debentures due Nov 2024

Gross proceeds $3.87M; offering included 1.16M shares, 2.04M pre-funded warrants, and 3.54M each of Series F-1/F-2/F-3 warrants.
July 11, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01

NovaBay reports prelim Q2 2024 net revenue $2.4M; eyecare revenue up 9% YoY

Preliminary Q2 2024 net revenue of $2.4M; H1 2024 net revenue $5.0M.
June 14, 2024, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 9.01

NovaBay enters warrant reprice transactions, expects ~$226K gross proceeds

Existing warrant holders exercise ~90,381 shares at reduced price of $2.50, providing ~$225,952.
June 7, 2024, 7:59 PM ET other material materiality 0.65 positive item 3.01 item 9.01

NovaBay gets NYSE American acceptance of compliance plan; trading continues with .BC indicator

NYSE American accepted plan on June 4, 2024; plan period runs through October 18, 2025.
May 31, 2024, 7:59 PM ET other material materiality 0.70 neutral item 9.01

NovaBay reports pro forma Q1 2024 net loss $2.3M after DERMAdoctor sale; 1:35 reverse split

Pro forma Q1 2024: product revenue $2.6M, net loss from cont. ops $2.3M (vs historical $3.1M).
May 31, 2024, 7:59 PM ET other material materiality 0.65 negative item 3.03 item 5.03 item 9.01

NovaBay effect 1-for-35 reverse stock split effective May 30, 2024

Reverse stock split at 1-for-35 ratio; effective 4:15 p.m. ET on May 30, 2024.
May 29, 2024, 7:59 PM ET other material materiality 0.75 negative item 3.01 item 5.07 item 8.01 item 9.01

NovaBay receives additional NYSE non-compliance notice; approves 1-for-35 reverse split

Stockholders' equity $160k as of March 31, below $2M minimum; delisting risk if not cured by Oct 2025.
April 22, 2024, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

NovaBay issues corporate update presentation; no specific financial figures disclosed.

Filed a corporate update presentation on April 22, 2024, discussing operations and business strategy.
April 19, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 8.01 item 9.01 ◈ Listing & Compliance Notices

NovaBay receives NYSE American delisting notice for insufficient stockholders' equity

Stockholders' equity was $3.3M as of Dec 31, 2023, below $4M and $6M thresholds.
March 26, 2024, 7:59 PM ET M&A materiality 0.55 neutral item 2.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ M&A Transactions

NovaBay sells DERMAdoctor for $1.07M; issues warrants/notes to secured parties

Sold wholly-owned subsidiary DERMAdoctor for $1,070,000, adjusted for debt and expenses.
March 25, 2024, 7:59 PM ET M&A materiality 0.70 neutral item 1.01 item 3.02 item 9.01

NovaBay sells DERMAdoctor for $1.07M; issues warrants/notes to secured parties as consent

Sale of DERMAdoctor to New Age Investments LLC for $1.07M, expected to close March 25, 2024.
March 14, 2024, 7:59 PM ET M&A materiality 0.75 negative item 1.01 item 2.02 item 9.01 ◈ Earnings Releases◈ Material Agreements

NovaBay sells DERMAdoctor skincare for $1.07M; reports Q4 net sales $3.7M, operating loss $3.2M

Sells DERMAdoctor for ~$1.07M cash to New Age Investments; closing expected by March 31, 2024.

Earnings & guidance

2026-Q1 EPS reported $3.33 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.70 · Most common event other_material

10 positive 15 negative 19 neutral

source · SDEV on sec.gov